Klotho Neurosciences (KLTO) shares surged by more than 400% in recent trading on Monday after the company said that initial findings in preclinical studies showed the potential of elevating Klotho gene expression to reduce age-related organ degeneration.
Findings of a study in mice showed that the higher concentration of the Klotho protein in serum resulted in a 20% increase in lifespan, according to the company.
Klotho said it has acquired an exclusive worldwide license for the molecule and will be able to use patents covering its use to treat neurodegenerative and age-related disorders.
Price: 0.98, Change: +0.78, Percent Change: +380.00
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.